244 related articles for article (PubMed ID: 17704246)
21. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.
Casado E; Gomez-Navarro J; Yamamoto M; Adachi Y; Coolidge CJ; Arafat WO; Barker SD; Wang MH; Mahasreshti PJ; Hemminki A; Gonzalez-Baron M; Barnes MN; Pustilnik TB; Siegal GP; Alvarez RD; Curiel DT
Clin Cancer Res; 2001 Aug; 7(8):2496-504. PubMed ID: 11489832
[TBL] [Abstract][Full Text] [Related]
22. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene.
Klutz K; Russ V; Willhauck MJ; Wunderlich N; Zach C; Gildehaus FJ; Göke B; Wagner E; Ogris M; Spitzweg C
Clin Cancer Res; 2009 Oct; 15(19):6079-86. PubMed ID: 19789324
[TBL] [Abstract][Full Text] [Related]
23. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
[TBL] [Abstract][Full Text] [Related]
24. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice.
Wang WB; Zhou YL; Heng DF; Miao CH; Cao YL
Breast Cancer Res Treat; 2008 Jul; 110(2):283-95. PubMed ID: 17899369
[TBL] [Abstract][Full Text] [Related]
25. Rat sodium iodide symporter for radioiodide therapy of cancer.
Mitrofanova E; Unfer R; Vahanian N; Daniels W; Roberson E; Seregina T; Seth P; Link C
Clin Cancer Res; 2004 Oct; 10(20):6969-76. PubMed ID: 15501976
[TBL] [Abstract][Full Text] [Related]
26. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
27. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
28. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
29. Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) promoter.
McCluskey AG; Mairs RJ; Sorensen A; Robson T; McCarthy HO; Pimlott SL; Babich JW; Champion S; Boyd M
Radiat Res; 2013 Mar; 179(3):282-92. PubMed ID: 23336184
[TBL] [Abstract][Full Text] [Related]
30. [Oncostatin M gene therapy in mice bearing lung adenocarcinoma xenograft using a hypoxia/radiation dual-sensitive promoter].
Wang WD; Chen ZT; Li DZ; Duan YZ; Wang ZX; Cao ZH
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Apr; 27(4):240-3. PubMed ID: 15144614
[TBL] [Abstract][Full Text] [Related]
31. Imaging hNET reporter gene expression with 124I-MIBG.
Moroz MA; Serganova I; Zanzonico P; Ageyeva L; Beresten T; Dyomina E; Burnazi E; Finn RD; Doubrovin M; Blasberg RG
J Nucl Med; 2007 May; 48(5):827-36. PubMed ID: 17475971
[TBL] [Abstract][Full Text] [Related]
32. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
33. [An experimental study on targeting suicide gene therapy for lung cancer with HSV-TK driven by hTERT promoter].
Wang YP; Tang XJ; Zhou QH; Che GW; Chen XH; Zhu DX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):701-5. PubMed ID: 19024294
[TBL] [Abstract][Full Text] [Related]
34. Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy.
Kawashita Y; Ohtsuru A; Miki F; Kuroda H; Morishita M; Kaneda Y; Hatsushiba K; Kanematsu T; Yamashita S
Gene Ther; 2005 Nov; 12(22):1633-9. PubMed ID: 16079887
[TBL] [Abstract][Full Text] [Related]
35. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo.
Song MS; Jeong JS; Ban G; Lee JH; Won YS; Cho KS; Kim IH; Lee SW
Cancer Gene Ther; 2009 Feb; 16(2):113-25. PubMed ID: 18758435
[TBL] [Abstract][Full Text] [Related]
36. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
Mairs RJ; Boyd M
Nucl Med Biol; 2008 Aug; 35 Suppl 1():S9-20. PubMed ID: 18707637
[TBL] [Abstract][Full Text] [Related]
37. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake.
Egami T; Ohuchida K; Mizumoto K; Onimaru M; Toma H; Nishio S; Nagai E; Matsumoto K; Nakamura T; Tanaka M
Clin Cancer Res; 2008 Mar; 14(6):1859-67. PubMed ID: 18347189
[TBL] [Abstract][Full Text] [Related]
38. The human norepinephrine transporter in combination with 11C-m-hydroxyephedrine as a reporter gene/reporter probe for PET of gene therapy.
Buursma AR; Beerens AM; de Vries EF; van Waarde A; Rots MG; Hospers GA; Vaalburg W; Haisma HJ
J Nucl Med; 2005 Dec; 46(12):2068-75. PubMed ID: 16330572
[TBL] [Abstract][Full Text] [Related]
39. The herpesvirus saimiri ORF 73 regulatory region provides long-term transgene expression in human carcinoma cell lines.
Giles MS; Smith PG; Coletta PL; Hall KT; Whitehouse A
Cancer Gene Ther; 2003 Jan; 10(1):49-56. PubMed ID: 12489028
[TBL] [Abstract][Full Text] [Related]
40. Tumor-targeting amino acid auxotrophic Salmonella typhimurium.
Hoffman RM
Amino Acids; 2009 Sep; 37(3):509-21. PubMed ID: 19291366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
